# Myeloid Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myeloid-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.myeloidtx.com
- Total disclosed funding: $108M
- Latest round: Series A (May 18, 2023)
- Investors on record: 6

## About

Myeloid Therapeutics, Inc. is a biotechnology company focused on developing mRNA-based immunotherapies aimed at activating myeloid cells to enhance anti-tumor immunity in oncology treatments.Founded in 2019 and headquartered in Cambridge, US, Myeloid Therapeutics specializes in mRNA-based immunotherapy innovations. Led by CEO Daniel Getts, the company has engaged in 4 deals, with the most recent deal occurring on May 18, 2023, during a Series A funding round where they raised USD 73.00 mn. Their primary investor was Hatteras Venture Partners, supported by other investors including 8VC and ARCH Venture Partners. The total amount raised by the company stands at USD 73.00 mn, with a current valuation of USD 154.50 mn.Myeloid Therapeutics specializes in mRNA-based immunotherapies, focusing on innovative therapies that utilize advanced cell and gene therapy methods. Their core product offerings include a novel in vivo engineering platform designed to target and activate myeloid cells within solid tumors, eliciting a broader anti-tumor adaptive immunity without ex-vivo cell engineering. Additionally, their retrotransposon-mediated gene insertion technology enhances therapeutic potential by delivering larger genetic sequences into the genome. The company’s technologies are aimed at healthcare providers, research institutions, and pharmaceutical companies across North America, Europe, and Asia, addressing significant unmet medical needs in oncology.Myeloid Therapeutics generates revenue through collaborations with pharmaceutical companies, research institutions, and healthcare providers. Their revenue model includes licensing agreements, co-development partnerships, and direct sales of proprietary therapies, particularly their mRNA therapies. These agreements are structured to foster long-term partnerships in the biotechnology sector, with revenue also augmented through milestone payments linked to clinical development and potential royalty agreements based on future sales.In May 2023, Myeloid Therapeutics raised USD 73.00 mn in Series A funding, led by Hatteras Venture Partners, to support its clinical development and cell therapy program. The company plans to further develop their mRNA-based products and is targeting expansion into new markets, particularly in Europe and Asia, with strategic timelines aimed at product launches within the next two years. This funding will enable them to enhance their therapeutic offerings while addressing the growing demand for advanced immunotherapies in oncology.

## Funding rounds

- Series A, May 18, 2023, $73M — ARCH Venture Partners, Alexandria Venture Investments, Hatteras Venture Partners, 8VC, Moore Strategic Ventures, Newpath Partners
- Series A, Aug 20, 2020, $35M — Alexandria Venture Investments, Hatteras Venture Partners, 8VC, Newpath Partners

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Series A
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Moore Strategic Ventures (https://capitalatlas.ai/funds/moore-strategic-ventures) — Series A